Research Library › Research Desk
The first Kalibra Research Pulse covers development news from the past several months on compounds in the Research Library: a first-of-its-kind FDA approval, a completed Phase 3 program, new trial readouts, a pending foreign application, and two notable items from the analytical and research-integrity literature.
Orforglipron becomes the first FDA-approved small-molecule GLP-1 agonist
On 1 April 2026 the FDA approved Eli Lilly’s orforglipron as Foundayo. It is a non-peptide small molecule that binds the GLP-1 receptor, unlike peptide-based compounds such as semaglutide. It was also the first new molecular entity cleared under the FDA’s National Priority Voucher pilot [1]. Lilly reported in August that it had also submitted the compound for type 2 diabetes [3]. Orforglipron reference page →
Retatrutide completes its initial Phase 3 program
Lilly reported in July that two further Phase 3 trials of retatrutide, TRIUMPH-2 and TRIUMPH-3, had completed. That finishes its initial registration program of four global trials [2]. In August the company said it plans to file with the FDA in the first quarter of 2027 [3]. Retatrutide is a single peptide designed to act at the GIP, GLP-1 and glucagon receptors. It is not approved anywhere. Retatrutide reference page →
Survodutide Phase III data presented
Boehringer Ingelheim presented results from the SYNCHRONIZE-1 and SYNCHRONIZE-MASLD trials of survodutide at the American Diabetes Association meeting in June. The company continues to describe the glucagon/GLP-1 dual agonist as investigational and not approved [4]. Survodutide reference page →
Tesofensine application still pending in Mexico
Saniona’s August interim report says its partner Medix is still working toward approval of tesofensine in Mexico, after resubmitting its application to the regulator COFEPRIS in February 2025 [5]. Tesofensine is a small-molecule monoamine reuptake inhibitor, not a peptide. Tesofensine reference page →
Anti-doping science catches up with SLU-PP-332
The WADA-accredited laboratory at the German Sport University Cologne published in vitro metabolism and detection data for SLU-PP-332 and its relative SLU-PP-915 [6]. Both are small-molecule estrogen-related receptor agonists that have only been studied preclinically. Work like this usually comes before a compound is screened for in sport. SLU-PP-332 reference page →
Research integrity: dihexa literature
PubMed now lists as retracted a 2014 paper from the group that developed dihexa. The paper proposed the compound’s link to the HGF/c-Met system [7]. The journal had already placed expressions of concern on four of the group’s papers in 2021. Readers relying on the early dihexa literature should take these notices into account. Dihexa reference page →
How this round-up is made
Each Research Pulse is compiled from company filings, regulator announcements and indexed journals, then checked against the primary source. We report what was announced or published, not what it might mean for anyone’s health. See our editorial standards.
Sources
- U.S. FDA. FDA approves first new molecular entity under National Priority Voucher program (orforglipron, Foundayo). 1 Apr 2026. Link
- Eli Lilly and Company. Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials (TRIUMPH-2, TRIUMPH-3). 23 Jul 2026. Link
- Eli Lilly and Company. Lilly reports second-quarter 2026 financial results. 5 Aug 2026. Link
- Boehringer Ingelheim. Survodutide Phase III SYNCHRONIZE-1 and SYNCHRONIZE-MASLD data at ADA 2026. 7 Jun 2026 (via PharmaShots). Link
- Saniona AB. Interim report January–June 2026. 27 Aug 2026. Link
- Möller T, Krug O, Thevis M. In vitro metabolism and analytical characterization of SLU-PP-332 and SLU-PP-915. Rapid Commun Mass Spectrom. 2026. Link
- PubMed record PMID 25187433 (Benoist et al. 2014, J Pharmacol Exp Ther), marked retracted. Link
The Kalibra Research Desk reports on published research and regulatory actions. It does not give medical, dosing or usage advice, and nothing here describes use in people or animals. Kalibra Labs products are for laboratory research use only.
